Prescription of long-acting opioids and mortality in patients with chronic noncancer pain

JAMA - Journal of the American Medical Association

Volumn 315, Issue 22, 2016, Pages 2415-2423

  Ray, Wayne A ^a   Chung, Cecilia P ^a   Murray, Katherine T ^a   Hall, Kathi ^a   Michael Stein, C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; FENTANYL; GABAPENTIN; LONG ACTING DRUG; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE; PREGABALIN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ADULT; ALL CAUSE MORTALITY; ARTICLE; BACKACHE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHRONIC PAIN; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; CARDIOVASCULAR DISEASE; DRUG OVERDOSE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

ANALGESICS, OPIOID; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHRONIC PAIN; DRUG OVERDOSE; DRUG PRESCRIPTIONS; FEMALE; FENTANYL; HUMANS; MALE; METHADONE; MIDDLE AGED; MORPHINE; OXYCODONE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK;

EID: 84974850911     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.7789     Document Type: Article

References (39)

1. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010;363(21):1981-1985.
2. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487-1492.
3. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009;181(12):891-896.
4. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85-92.
5. Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011; 305(13):1315-1321.
6. Correa D, Farney RJ, Chung F, Prasad A, Lam D, Wong J. Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg. 2015; 120(6):1273-1285.
7. Mansukhani MP, Wang S, Somers VK. Sleep, death, and the heart. Am J Physiol Heart Circ Physiol. 2015;309(5):H739-H749.
8. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4): 276-286.
9. Menendez ME, Ring D, Bateman BT. Preoperative opioid misuse is associated with increased morbidity and mortality after elective orthopaedic surgery. Clin Orthop Relat Res. 2015; 473(7):2402-2412.
10. Brack A, Rittner HL, Stein C. Immunosuppressive effects of opioids-clinical relevance. J Neuroimmune Pharmacol. 2011;6(4):490-502.
11. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8(3):181-186.
12. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;(3):CD007938.
13. Pedersen L, Hansen AB, Svendsen K, Skurtveit S, Borchgrevink PC, Fredheim OM. Reimbursement of analgesics for chronic pain. Tidsskr Nor Laegeforen. 2012;132(22):2489-2493.
14. Carragee EJ. Persistent low back pain. N Engl J Med. 2005;352(18):1891-1898.
15. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther. 2004; 75(3):234-241.
16. Ray WA, Chung CP, Murray KT, Cooper WO, Hall K, Stein CM. Out-of-hospital mortality among patients receiving methadone for noncancer pain. JAMA Intern Med. 2015;175(3):420-427.
17. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol. 1989;129 (4):837-849.
18. Ray WA. Population-based studies of adverse drug effects. N Engl J Med. 2003;349(17):1592-1594.
19. Piper JM, Ray WA, Griffin MR, Fought R, Daughtery JR, Mitchel E Jr. Methodological issues in evaluating expanded Medicaid coverage for pregnant women. Am J Epidemiol. 1990;132(3): 561-571.
20. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA. 2016;315(15): 1624-1645.
21. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.
22. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349(20):1943-1953.
23. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698.
24. Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med. 2015;175(4):608-615.
25. Shadish WR, Steiner PM. A primer on propensity score analysis. Newborn Infant Nurs Rev. 2010;10:19-26.
26. Allison PD. Survival Analysis Using SAS: A Practical Guide. 2nd ed. Cary, NC: SAS Institute Inc; 2010.
27. Ray WA, Liu Q, Shepherd BE. Performance of time-dependent propensity scores: a pharmacoepidemiology case study. Pharmacoepidemiol Drug Saf. 2015;24(1):98-106.
28. Arbogast PG, Kaltenbach L, Ding H, Ray WA. Adjustment for multiple cardiovascular risk factors using a summary risk score. Epidemiology. 2008;19 (1):30-37.
29. Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res. 2009;18(1):67-80.
30. Arbogast PG, Ray WA. Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders. Am J Epidemiol. 2011;174 (5):613-620.
31. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173.
32. Chou R, Huffman LH; American Pain Society; American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med. 2007;147(7):505-514.
33. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;12:CD008242.
34. Ghinea N, Lipworth W, Kerridge I. Evidence, regulation and "rational" prescribing: the case of gabapentin for neuropathic pain. J Eval Clin Pract. 2015;21(1):28-33.
35. Yue HJ, Guilleminault C. Opioid medication and sleep-disordered breathing. Med Clin North Am. 2010;94(3):435-446.
36. Zutler M, Holty JE. Opioids, sleep, and sleep-disordered breathing. Curr Pharm Des. 2011; 17(15):1443-1449.
37. Lee-Iannotti J, Parish JM. The epidemic of opioid use: implications for the sleep physician. J Clin Sleep Med. 2014;10(6):645-646.
38. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968-1976.
39. Centers for Disease Control and Prevention (CDC). Overdose deaths involving prescription opioids among Medicaid enrollees-Washington, 2004-2007. MMWR Morb Mortal Wkly Rep. 2009; 58(42):1171-1175.